The River Blindness Drug Ivermectin and Related Macrocyclic Lactones Inhibit WNT-TCF Pathway Responses in Human Cancer

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2014 Aug 22

PMID 25143352

Citations 60

Authors

Alice Melotti

Christophe Mas

Monika Kuciak

Aiala Lorente-Trigos

Isabel Borges

Ariel Ruiz i Altaba

Affiliations

Soon will be listed here.

Abstract

Constitutive activation of canonical WNT-TCF signaling is implicated in multiple diseases, including intestine and lung cancers, but there are no WNT-TCF antagonists in clinical use. We have performed a repositioning screen for WNT-TCF response blockers aiming to recapitulate the genetic blockade afforded by dominant-negative TCF. We report that Ivermectin inhibits the expression of WNT-TCF targets, mimicking dnTCF, and that its low concentration effects are rescued by direct activation by TCF(VP16). Ivermectin inhibits the proliferation and increases apoptosis of various human cancer types. It represses the levels of C-terminal β-CATENIN phosphoforms and of CYCLIN D1 in an okadaic acid-sensitive manner, indicating its action involves protein phosphatases. In vivo, Ivermectin selectively inhibits TCF-dependent, but not TCF-independent, xenograft growth without obvious side effects. Analysis of single semi-synthetic derivatives highlights Selamectin, urging its clinical testing and the exploration of the macrocyclic lactone chemical space. Given that Ivermectin is a safe anti-parasitic agent used by > 200 million people against river blindness, our results suggest its additional use as a therapeutic WNT-TCF pathway response blocker to treat WNT-TCF-dependent diseases including multiple cancers.

Citing Articles

Apoptosis-Inducing and Proliferation-Inhibiting Effects of Doramectin on Mz-ChA-1 Human Cholangiocarcinoma Cells.

Zhang Y, Wu W, Shi Y, Huang Y, Dai T, Ke L Int J Mol Sci. 2025; 25(24.

PMID: 39769205 PMC: 11676298. DOI: 10.3390/ijms252413440.

Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy.

Gaikwad S, Srivastava S Mol Ther. 2024; 32(9):3145-3162.

PMID: 39097773 PMC: 11403213. DOI: 10.1016/j.ymthe.2024.07.029.

The Gene Network That Regulates Head Organizer Activity in Is Differentially Regulated in Epidermis and Gastrodermis.

Iglesias Olle L, Perruchoud C, Sanchez P, Vogg M, Galliot B Biomedicines. 2024; 12(6).

PMID: 38927481 PMC: 11201823. DOI: 10.3390/biomedicines12061274.

Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors.

Allegra A, Mirabile G, Caserta S, Stagno F, Russo S, Pioggia G Antioxidants (Basel). 2024; 13(4).

PMID: 38671909 PMC: 11047441. DOI: 10.3390/antiox13040461.

Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.

Fan N, Zhang L, Wang Z, Ding H, Yue Z Anticancer Agents Med Chem. 2024; 24(5):348-357.

PMID: 38375808 DOI: 10.2174/0118715206274095231106042833.

References

Lepourcelet M, Chen Y, France D, Wang H, Crews P, Petersen F . Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1):91-102. DOI: 10.1016/s1535-6108(03)00334-9. View

Sharmeen S, Skrtic M, Sukhai M, Hurren R, Gronda M, Wang X . The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 2010; 116(18):3593-603. DOI: 10.1182/blood-2010-01-262675. View

Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K . Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012; 67(8):1884-94. PMC: 3888155. DOI: 10.1093/jac/dks147. View

Hino S, Tanji C, Nakayama K, Kikuchi A . Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol. 2005; 25(20):9063-72. PMC: 1265785. DOI: 10.1128/MCB.25.20.9063-9072.2005. View

Anastas J, Moon R . WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2012; 13(1):11-26. DOI: 10.1038/nrc3419. View

Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson S . A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012; 72(11):2822-32. DOI: 10.1158/0008-5472.CAN-11-3336. View

Zhao J, Yue W, Zhu M, Sreejayan N, Du M . AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochem Biophys Res Commun. 2010; 395(1):146-51. PMC: 2864303. DOI: 10.1016/j.bbrc.2010.03.161. View

Nguyen D, Chiang A, Zhang X, Kim J, Kris M, Ladanyi M . WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009; 138(1):51-62. PMC: 2742946. DOI: 10.1016/j.cell.2009.04.030. View

Shitashige M, Hirohashi S, Yamada T . Wnt signaling inside the nucleus. Cancer Sci. 2008; 99(4):631-7. PMC: 11158179. DOI: 10.1111/j.1349-7006.2007.00716.x. View

10.

Ziskin J, Dunlap D, Yaylaoglu M, Fodor I, Forrest W, Patel R . In situ validation of an intestinal stem cell signature in colorectal cancer. Gut. 2012; 62(7):1012-23. DOI: 10.1136/gutjnl-2011-301195. View

11.

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

12.

Seeling J, Miller J, Gil R, Moon R, White R, Virshup D . Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999; 283(5410):2089-91. DOI: 10.1126/science.283.5410.2089. View

13.

Schinkel A, Smit J, van Tellingen O, Beijnen J, Wagenaar E, van Deemter L . Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77(4):491-502. DOI: 10.1016/0092-8674(94)90212-7. View

14.

Nolan T, Lok J . Macrocyclic lactones in the treatment and control of parasitism in small companion animals. Curr Pharm Biotechnol. 2011; 13(6):1078-94. DOI: 10.2174/138920112800399167. View

15.

MacDonald B, Tamai K, He X . Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009; 17(1):9-26. PMC: 2861485. DOI: 10.1016/j.devcel.2009.06.016. View

16.

van der Flier L, van Gijn M, Hatzis P, Kujala P, Haegebarth A, Stange D . Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell. 2009; 136(5):903-12. DOI: 10.1016/j.cell.2009.01.031. View

17.

Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt S, Borges I, Ruiz i Altaba A . NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010; 29(15):2659-74. PMC: 2928692. DOI: 10.1038/emboj.2010.137. View

18.

Drinyaev V, Mosin V, Kruglyak E, Novik T, Sterlina T, Ermakova N . Antitumor effect of avermectins. Eur J Pharmacol. 2004; 501(1-3):19-23. DOI: 10.1016/j.ejphar.2004.08.009. View

19.

Traore M, Sarr M, Badji A, Bissan Y, Diawara L, Doumbia K . Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012; 6(9):e1825. PMC: 3441490. DOI: 10.1371/journal.pntd.0001825. View

20.

Dodge M, Moon J, Tuladhar R, Lu J, Jacob L, Zhang L . Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine. J Biol Chem. 2012; 287(27):23246-54. PMC: 3391103. DOI: 10.1074/jbc.M112.372029. View